Other languages Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 EDT			5-day change	1st Jan Change
2,668 ^JPY	0.00%		+0.45%	+12.55%

04:33pm	BridgeBio Pharma Shares Decline After Q1 Financial Results	MT
04-08	U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BridgeBio Pharma Shares Decline After Q1 Financial Results	10:33am
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	04-08
Japanese Shares Slip into Red Amid Profit-Taking; Tokyo Inflation Eyed	03-25
Kyowa Kirin to Allocate Over 84,000 Treasury Shares as Director, Officer Compensation	03-25
Kyowa Kirin's gene therapy most expensive US drug with $4.3 million price tag	03-20
EEUU aprueba la primera terapia de genes para niños con una rara enfermedad hereditaria	03-18
US approves first gene therapy for children with rare genetic disease	03-18
US approves first gene therapy for rare genetic disease	03-18
Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024	03-08
Kyowa Kirin Buys Back Nearly 3 Billion Yen of Shares	03-05
China Deflation, Bank of Japan Roil Asian Stock Markets	02-08
MÄRKTE ASIEN/Tokio sehr fest auf 34-Jahreshoch - Softbank mit Kurssprung	02-08
Japan's Nikkei closes at 34-year peak on dovish BOJ; tech shares soar	02-08
Japan's Nikkei leaps to 2-week high on tech stocks, yen boost	02-07
BridgeBio Pharma Unit to Grant Kyowa Kirin License for Infigratinib in Japan	02-07
Kyowa Kirin's Profit Up 52% in Fiscal 2023	02-07
Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2024	02-07
Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024	02-07
Kyowa Kirin Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024	02-07
Kyowa Kirin Co., Ltd. announces an Equity Buyback for 17,000,000 shares, representing 3.16% for KRW 40,000 million.	02-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kyowa Kirin Co. Ltd.

Equities

4151

JP3256000005

Other languages

Filters